Report
Windward Bio files for US IPO to fund antibody-drug trials
Reuters reports Windward aims to reduce injection frequency with antibody treatments for asthma, COPD and inflammatory skin conditions.
TLDR
Reuters reports that Swiss drug developer Windward Bio filed for a US IPO and plans to list on Nasdaq under “WWB.” Bloomberg says the offering would help fund antibody-drug trials: one candidate for severe asthma and COPD is in advanced trials, while another for inflammatory diseases including eczema is in early-stage trials.
Combined views
45.6K
2 Sources, first seen ago